Clinical trials of AstraZeneca
The British drugmaker said on Friday the early-to-mid-stage trial for the vaccine against the novel coronavirus resumed in Japan after consultations with the national health regulator, the Japanese Pharmaceuticals and Medical Devices Agency.
Global trials of the vaccine, called AZD1222 or ChAdOx1 nCoV-19, were put on hold on Sept. 6 after a study participant fell ill with what was believed to be a rare spinal inflammatory disorder called transverse myelitis.
Trials in the UK, Brazil, South Africa and India had already restarted, but U.S. trials remain paused as regulators widened their probe, Reuters reported on Wednesday.
AstraZeneca has called the halt a standard review procedure, and a document posted online by Oxford university last month stated the illness may not have been associated with the vaccine.
However, the incident has drawn focus on the safety of candidates being developed in the race for a successful vaccine against the illness caused by the novel coronavirus which has claimed more than a million lives globally.
The U.S. Food and Drug Administration (FDA) broadened its investigation of the illness in the volunteer, and would look at data from earlier trials of similar vaccines developed by the same scientists, three sources told Reuters.
In Friday's statement, AstraZeneca stressed that safety of the participants was of "paramount importance" and that it was applying the highest standards of conduct in trials.
Sources had told Reuters that the data requested by the FDA for one of the most advanced COVID-19 vaccine candidates in development was expected this week.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU